However, no studies have examined the effect of empagliflozin or the combination of DPP-4 inhibitors and SGLT2 inhibitors on the development of NASH in the presence of diabetes. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.